LABD

Direxion Daily S&P Biotech Bear 3X Shares [LABD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

LABD Stock Summary

Top 10 Correlated ETFs

LABD

In the News

LABD Financial details

Company Rating
-
Market Cap
146.09M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.11
Dividend %
5.24%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
5.36%
SMA50
-22.93%
SMA100
-25.92%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.72-29.92
52W High
-54.52%
52W Low
+163.8%
RSI
44.84
Rel Volume
0.46
Avg Volume
15.43M
Volume
7.09M
Perf Week
-10.33%
Perf Month
-11.06%
Perf Quarter
-42%
Perf Half Y
-38.88%
-
-
-
-
Beta
-2.44
-
-
Volatility
0.73%, 0.87%
Prev Close
-2.15%
Price
13.19
Change
-10.45%

LABD Financial Performance

LABD Dividend History

LABD Frequently Asked Questions

What is Direxion Daily S&P Biotech Bear 3X Shares stock symbol ?

Direxion Daily S&P Biotech Bear 3X Shares is a US stock and trading under the symbol LABD

What is Direxion Daily S&P Biotech Bear 3X Shares stock quote today ?

Direxion Daily S&P Biotech Bear 3X Shares stock price is $13.19 today.

Is Direxion Daily S&P Biotech Bear 3X Shares stock public?

Yes, Direxion Daily S&P Biotech Bear 3X Shares is a publicly traded company.

Something similar

Top by Market Cap
TL0.DE
M&M.NS
EMBASSY.NS
JPM
AVGO
Top Correlated ETFs
BIS
Same Price Range
SMTO3.SA
300012.SZ
601865.SS
DPP.L
VOD
Similar Market Cap
HOWL
FREEW
ORIAU
EFAD
AYFIE.OL

Company Profile

Financial Services Asset Management - Leveraged
  • Volume Average 15.43M
  • Market Capitalization 146.09M
  • Headquarters US
  • IPO Date 2015-05-28

The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.